- Home
- ARHS vs OCS Comparison
ARHS vs OCS Comparison
Compare ARHS & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- OCS
- Stock Information
- Founded
- ARHS 1986
- OCS 2003
- Country
- ARHS United States
- OCS Switzerland
- Employees
- ARHS N/A
- OCS N/A
- Industry
- ARHS Other Specialty Stores
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- ARHS Consumer Discretionary
- OCS Health Care
- Exchange
- ARHS Nasdaq
- OCS Nasdaq
- Market Cap
- ARHS 1.2B
- OCS 1.0B
- IPO Year
- ARHS 2021
- OCS N/A
- Fundamental
- Price
- ARHS $9.22
- OCS $18.16
- Analyst Decision
- ARHS Buy
- OCS Strong Buy
- Analyst Count
- ARHS 14
- OCS 3
- Target Price
- ARHS $11.08
- OCS $35.33
- AVG Volume (30 Days)
- ARHS 1.6M
- OCS 19.8K
- Earning Date
- ARHS 08-07-2025
- OCS 08-26-2025
- Dividend Yield
- ARHS N/A
- OCS N/A
- EPS Growth
- ARHS N/A
- OCS N/A
- EPS
- ARHS 0.41
- OCS N/A
- Revenue
- ARHS $1,287,317,000.00
- OCS $847,333.00
- Revenue This Year
- ARHS $7.07
- OCS $10.23
- Revenue Next Year
- ARHS $7.64
- OCS $912.87
- P/E Ratio
- ARHS $22.47
- OCS N/A
- Revenue Growth
- ARHS 0.71
- OCS N/A
- 52 Week Low
- ARHS $6.61
- OCS $10.79
- 52 Week High
- ARHS $17.27
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- ARHS 55.66
- OCS 36.59
- Support Level
- ARHS $8.80
- OCS $18.87
- Resistance Level
- ARHS $9.78
- OCS $19.24
- Average True Range (ATR)
- ARHS 0.44
- OCS 0.41
- MACD
- ARHS 0.03
- OCS -0.17
- Stochastic Oscillator
- ARHS 61.69
- OCS 0.00
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.